Merck and Moderna’s personalized mRNA cancer vaccine has reportedly met its primary goal in a late-stage trial involving melanoma patients. The treatment is designed to train the immune system to recognize tumor-specific markers, potentially reducing the risk of recurrence after surgery. Researchers said the findings support further development, though additional analysis and regulatory review are still required. The companies are expected to study the approach in other cancers and assess its long-term effectiveness and safety for patients
Published by Banx Network. This article is part of the Banx decentralized media programme, powered by the BXE token on the XRP Ledger.
